{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T19:50:36Z","timestamp":1760385036894},"reference-count":16,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","mayoclinicproceedings.org","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.4065\/mcp.2010.0267","type":"journal-article","created":{"date-parts":[[2010,5,28]],"date-time":"2010-05-28T17:33:16Z","timestamp":1275067996000},"page":"508-511","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["New Uses for Older Drugs: The Tales of Aspirin, Thalidomide, and Gabapentin"],"prefix":"10.4065","volume":"85","author":[{"given":"Joseph I.","family":"Sirven","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.4065\/mcp.2010.0267_bib1","doi-asserted-by":"crossref","first-page":"512","DOI":"10.4065\/mcp.2009.0700","article-title":"Long-term maintenance treatment of restless legs syndrome with gabapentin enacarbil: a randomized controlled study","volume":"85","author":"Bogan","year":"2010","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"10.4065\/mcp.2010.0267_bib2","doi-asserted-by":"crossref","first-page":"527","DOI":"10.4065\/mcp.2010.0042","article-title":"Opsoclonus-myoclonus syndrome in patients with locked-in syndrome: a therapeutic porthole with gabapentin","volume":"85","author":"Pistoia","year":"2010","journal-title":"Mayo Clin Proc"},{"key":"10.4065\/mcp.2010.0267_bib4","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/jlac.18530870206","article-title":"Untersuchungen \u00fcber die wasserfreien organischen S\u00e4uren","volume":"87","author":"Gerhardt","year":"1853","journal-title":"Annalen der Chemie und Pharmacie"},{"issue":"25","key":"10.4065\/mcp.2010.0267_bib5","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/newbio231232a0","article-title":"Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs","volume":"231","author":"Vane","year":"1971","journal-title":"Nat New Biol"},{"issue":"6","key":"10.4065\/mcp.2010.0267_bib6","doi-asserted-by":"crossref","first-page":"405","DOI":"10.7326\/0003-4819-150-6-200903170-00009","article-title":"Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force","volume":"150","author":"Wolff","year":"2009","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.4065\/mcp.2010.0267_bib7","doi-asserted-by":"crossref","first-page":"396","DOI":"10.7326\/0003-4819-150-6-200903170-00008","article-title":"Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement","volume":"150","author":"U.S. Preventive Services Task Force","year":"2009","journal-title":"Ann Intern Med"},{"issue":"7","key":"10.4065\/mcp.2010.0267_bib8","doi-asserted-by":"crossref","first-page":"899","DOI":"10.4065\/79.7.899","article-title":"Thalidomide: tragic past and promising future","volume":"79","author":"Rajkumar","year":"2004","journal-title":"Mayo Clin Proc"},{"key":"10.4065\/mcp.2010.0267_bib9","author":"Bren"},{"key":"10.4065\/mcp.2010.0267_bib10","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1177\/106002809402801011","article-title":"Gabapentin: a new agent for the management of epilepsy","volume":"28","author":"Andrews","year":"1994","journal-title":"Ann Pharmacother"},{"key":"10.4065\/mcp.2010.0267_bib11","doi-asserted-by":"crossref","first-page":"5768","DOI":"10.1074\/jbc.271.10.5768","article-title":"The novel anticonvulsant drug, gabapentin (Neurontin), binds to the \u03b12\u03b4 subunit of a calcium channel","volume":"271","author":"Gee","year":"1996","journal-title":"J Biol Chem"},{"key":"10.4065\/mcp.2010.0267_bib12","author":"Weinstein"},{"issue":"8","key":"10.4065\/mcp.2010.0267_bib13","doi-asserted-by":"crossref","first-page":"549","DOI":"10.2165\/00023210-200216080-00004","article-title":"Newer antiepileptic drugs in bipolar disorder: rationale for use and role in therapy","volume":"16","author":"Macdonald","year":"2002","journal-title":"CNS Drugs"},{"issue":"6","key":"10.4065\/mcp.2010.0267_bib14","first-page":"559","article-title":"Examination of the evidence for off-label use of gabapentin","volume":"9","author":"Mack","year":"2003","journal-title":"J Manag Care Pharm"},{"issue":"20","key":"10.4065\/mcp.2010.0267_bib15","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1056\/NEJMsa0906126","article-title":"Outcome reporting in industry sponsored trials of gabapentin for off-label use","volume":"361","author":"Vedula","year":"2009","journal-title":"N Engl J Med"},{"key":"10.4065\/mcp.2010.0267_bib16","article-title":"Pfizer pays $2.3 billion to settle marketing case","author":"Harris","year":"2009","journal-title":"New York Times"},{"key":"10.4065\/mcp.2010.0267_bib17","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1001\/archinte.166.9.1021","article-title":"Off-label prescribing among office-based physicians","volume":"166","author":"Radley","year":"2006","journal-title":"Arch Intern Med"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611603406?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611603406?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T22:02:28Z","timestamp":1675807348000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619611603406"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":16,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["S0025619611603406"],"URL":"https:\/\/doi.org\/10.4065\/mcp.2010.0267","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2010,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New Uses for Older Drugs: The Tales of Aspirin, Thalidomide, and Gabapentin","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4065\/mcp.2010.0267","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.4065\/mcp.2009.0700","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.4065\/mcp.2010.0042","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}